← FDA DRUG APPROVALS

FDA NDA · NDA212527

DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE

Sponsor: CIPLA USA INC.

APPLICATION
NDA212527
TYPE
NDA
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)

Products

DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDENone (Tentative Approval)
DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE EQ 50MG BASE · TABLET

Approval history

2022-03-30Type 4 - New Combination · Original · standard — Letter ↗TA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →